AIM
IBRX icon

Acrospire Investment Management’s ImmunityBio IBRX Stock Holding History

Acrospire Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,100
Closed -$16K – 2305
2016
Q3 		$16K Sell
2,100
-100
-5% -$747 0.01% 1573
2016
Q2 		$14K Buy
2,200
+1,500
+214% +$11.6K 0.01% 1645
2016
Q1 		$6K Buy
+700
New +$6.6K ﹤0.01% 1840

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acrospire Investment Management's IBRX Position: Q4 2016 in Review

Acrospire Investment Management sold out of ImmunityBio (IBRX) in Q4 2016, closing a stake of 2,100 shares — an estimated $16K sold.

Acrospire Investment Management first reported a position in IBRX in Q1 2016 and held it in 3 quarters. The position peaked at $16K in Q3 2016. 68 funds tracked by Wall St. Rank hold IBRX as of Q4 2016.

  • Acrospire Investment Management reported no remaining ImmunityBio position as of Q4 2016 after selling out during the quarter.
  • Acrospire Investment Management sold 2,100 ImmunityBio shares in Q4 2016, an estimated $16K.
  • Acrospire Investment Management first reported a position in ImmunityBio in Q1 2016 and held it in 3 quarters.
  • Acrospire Investment Management's ImmunityBio position peaked at $16K in Q3 2016.
  • 68 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2016.

Based on Acrospire Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.